Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Inclusion Criteria: * 18 ≤age≤70 years of age,male; * Hemophilia A or B patients; * A bleeding event requiring treatment occurred (Only applicable to the on-demand treatment stage); * Factor VIII or IX level \<2%, inhibitor titer \< 0.6 BU; * There were at least 2 bleeding events that requiring treatment occurred in the past 6 months before screening (Only the second stage is applicable); * Establish proper venous access; * Agree to use adequate contraception to avoid pregnancy; * Provide signed informed consent. Exclusion Criteria: * Have any coagulation disorder other than hemophilia; * Plan to receive prophylactic treatment of coagulation factor during the trail; * 4 weeks before screening, receive prophylactic treatment of amesetuzumab or plan to receive prophylactic treatment of amesetuzumab during the trial; * Patients received anticoagulant or antifibrinolytic therapy 7 days before enrollment or plan to receive these drugs during the trial; * Patients received anticoagulation therapy (such as coagulation factor replacement therapy, prothrombin complex, plasma, etc.) 7 days before enrollment; * Have a history of arterial and/or venous thrombotic events; * Platelet \<100×109/L; * Hemoglobin\<90g/L; * Severe liver or kidney disease; * Severe bleeding event occurred within 4 weeks before enrollment; * Accepted major operation or blood transfusion within 4 weeks before enrollment; * HIV positive; * Have a known allergy to STSP-0601; * Participate in other clinical research within 4 weeks before enrollment(except for participating in prothrombin complex, FVII, FVIIa, FVIII, FIX trails); * Patients not suitable for the trail according to the judgment of the investigators.